Virtus Advisers LLC Buys New Position in Sarepta Therapeutics, Inc. $SRPT

Virtus Advisers LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, HoldingsChannel.com reports. The fund bought 27,098 shares of the biotechnology company’s stock, valued at approximately $487,000.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $341,339,000. Vanguard Group Inc. grew its stake in Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after acquiring an additional 993,283 shares during the period. AQR Capital Management LLC grew its stake in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after acquiring an additional 6,390,860 shares during the period. First Trust Advisors LP grew its stake in Sarepta Therapeutics by 107.6% in the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock worth $89,995,000 after acquiring an additional 2,143,211 shares during the period. Finally, Erste Asset Management GmbH raised its holdings in Sarepta Therapeutics by 1.6% in the 4th quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock valued at $58,727,000 after acquiring an additional 43,000 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SRPT. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Finally, Piper Sandler decreased their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $19.22 on Friday. The firm has a market capitalization of $2.03 billion, a PE ratio of -6.63, a P/E/G ratio of 0.29 and a beta of 0.23. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. The business has a 50-day moving average of $17.35 and a two-hundred day moving average of $18.30. Sarepta Therapeutics, Inc. has a 12 month low of $14.68 and a 12 month high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The company’s quarterly revenue was down 34.3% compared to the same quarter last year. During the same period last year, the business posted $2.02 EPS. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.